Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?
Executive Summary
FDA may be able to talk in theoretical terms about the flexibility it is afforded for orphan products approvals, but others seem to want more tangible evidence. For its part, the agency wants more than general complaints about its regulations; it wants an open discussion of specific roadblocks.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
